Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

En effektivitets- og sikkerhetsstudie av DFL24498 i behandlingen av AKC

16. september 2026 oppdatert av: Dompé Farmaceutici S.p.A

A Phase 3, Multicenter, Randomized, Double-Masked, Vehicle-Controlled Study to Demonstrate Efficacy and Safety of DFL24498 Eye Drop Solution in Participants With Atopic Keratoconjunctivitis (AKC)

This is a phase 3, multicenter, randomized, double-masked, parallel-group, vehicle-controlled study to evaluate the safety and efficacy of DFL24498 compared with vehicle ophthalmic solution, in participants with AKC. The study consists of 2 cohorts: the adult cohort includes approximately 138 participants and the pediatric cohort which includes approximately 15 participants. The cohorts will be randomized separately. Adult participants will be randomized in a 1:1 ratio, while pediatric participants will be randomized in a 2:1 ratio to receive DFL24498 or vehicle.

Studieoversikt

Status

Rekruttering

Forhold

Intervensjon / Behandling

Detaljert beskrivelse

The study will consist of 3 periods:

  1. Washout period (from Day -7 ± 1 to Day 1),
  2. Treatment Period (from randomization through Week12) and
  3. Follow-up period (Weeks 13 to 16).

Studietype

Intervensjonell

Registrering (Antatt)

153

Fase

  • Fase 3

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

  • Navn: Dompé farmaceutici S.p.A. Via Santa Lucia, 6, 20122 Milan (MI)
  • Telefonnummer: +39 02 583 831

Studiesteder

    • Florida
      • Jacksonville, Florida, Forente stater, 32256
        • Rekruttering
        • Bowden Eye Associates - Southside Location
      • Miami, Florida, Forente stater, 33136
        • Rekruttering
        • University of Miami, Miller School of Medicine, Bascom Palmer Eye Institute
    • Georgia
      • Morrow, Georgia, Forente stater, 30260
        • Rekruttering
        • Clayton Eye Clinical Research
    • Missouri
      • St Louis, Missouri, Forente stater, 63131
        • Rekruttering
        • Ophthalmology Associates
    • New York
      • New York, New York, Forente stater, 10017
        • Rekruttering
        • NYU Langone Health - Eye Center
    • North Carolina
      • Durham, North Carolina, Forente stater, 27710
        • Rekruttering
        • Duke Eye Center - Ophthalmology
    • Tennessee
      • Memphis, Tennessee, Forente stater, 38119
        • Rekruttering
        • Total Eye Care, PA
    • Texas
      • Houston, Texas, Forente stater, 77030
        • Rekruttering
        • Baylor University Jamail Specialty Care Center- Alkek Eye Center- Ophthalmology
      • Bologna, Italia, 40138
        • Rekruttering
        • IRCCS AOU di Bologna - Policlinico Sant'Orsola UO Oftalmologia
      • Chieti, Italia, 66100
        • Rekruttering
        • Ospedale SS Annunziata, ASL 2 Lanciano Vasto Chieti
      • Florence, Italia, 50134
        • Rekruttering
        • Azienda Ospedaliero Universitaria Careggi
      • Roma, Italia, 00161
        • Rekruttering
        • AOU Policlinico Umberto I
      • Roma, Italia, 00128
        • Rekruttering
        • Fondazione Policlinico Universitario Campus Bio-Medico
      • Verona, Italia, 37134
        • Rekruttering
        • Azienda Ospedaliera Universitaria Integrata Verona
      • Córdoba, Spania, 14012
        • Rekruttering
        • METAVISION ARRUZAFA S.L. (Hospital Arruzafa)
      • Santiago de Compostela, Spania, 15706
        • Rekruttering
        • Miranza Galicia
      • Valencia, Spania, 46015
        • Rekruttering
        • Fundación de Oftalmología Médica de la Comunitat Valenciana (FOM)
      • Valladolid, Spania, 47011
        • Rekruttering
        • OBA - Universidad de Valladolid
      • Zaragoza, Spania, 50009
        • Rekruttering
        • Hospital Universitario Miguel Servet

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

10 år til 65 år (Barn, Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

Participants are eligible to be included in the study only if all of the following criteria apply:

  1. Male or Female aged ≥ 10 and ≤ 65 years.

  2. Diagnosis of AKC in both eyes, including the presence or medical history of the following:

    1. other atopic condition (ie., atopic dermatitis, periocular eczema, asthma, allergic rhinitis), AND
    2. chronic allergic blepharoconjunctivitis and/or keratoconjunctivitis.
  3. Ocular itching of at least 50 as assessed by VAS scale.

  4. Corneal fluorescein staining assessed by modified Oxford scale of at least grade 1 AND a bulbar conjunctival hyperemia assessed by VBR 10 scale of at least 40 (range 0 to 100) in the same eye.

  5. A composite symptoms score (CSyS) ≥ 5 (sum of the severity scores graded 0 to 3 for each of the following: itching, tearing, ocular discomfort, photophobia, and mucous discharge score) (CSyS range of 0 to 15).

  6. If a woman of childbearing potential (WOCBP), must have a negative pregnancy test at both screening and baseline visit, and use an acceptable contraception method.

Exclusion Criteria:

Participants will be excluded if any of the following criteria apply:

  1. Inability to speak and understand the local language sufficiently to understand the nature of the study, to provide written informed consent, and to allow the completion of all study assessments.
  2. Evidence of an active ocular infection in either eye.
  3. Intraocular inflammation defined as anterior chamber flare > 0 by Standardization of Uveitis Nomenclature (SUN) grading, in either eye.
  4. Known or suspected ocular malignancy (ocular surface, intraocular, ocular adnexa).
  5. Presence of cancer or any other systemic or unstable disease that may affect the ability to participate in the clinical study in the opinion of the investigator including basal cell carcinoma.
  6. Participants that are anatomically monocular.
  7. Systemic disease not stabilized within 1 month before the screening visit (eg, diabetes with glycemia out of range, thyroid malfunction) or judged by the investigator to be incompatible with the study (eg, current systemic infections) or with a condition incompatible with the frequent assessment required by the study.

Note: Additional protocol defined Inclusion/Exclusion criteria apply

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Trippel

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: DFL24498

Participants will be administered with DFL24498 eye drops in both eyes.

DFL24498 will be instilled in each eye for 12 Weeks.

Rescue medication may be administered as required at the Investigator discretion.

Placebo komparator: Vehicle

Participants will be administered with vehicle eye drops in both eyes.

Rescue medication may be administered as required at the Investigator discretion.

Vehicle eye drops without active drug will be instilled in each eye for 12 Weeks.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change from baseline at week 6 in ocular itching score assessed by visual analog scale (VAS).
Tidsramme: Baseline and at Week 6

The ocular itching VAS ranges from 0 to 100 mm (0 mm = no ocular itching at all, 100 mm = intolerable itching). Participants will be asked to subjectively rate the current severity of ocular itching at each time point.

Baseline and at Week 6

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change from baseline at week 6 in corneal epithelial fluorescein staining, scored by modified Oxford scale, in the study eye.
Tidsramme: Baseline and at Week 6

Fluorescein will be applied to the inferior fornix of the palpebral conjunctiva of each eye. To avoid the phenomenon of quenching, staining will be assessed within 1 to 4 minutes from fluorescein instillation. Examination will be performed at the slit-lamp using blue (cobalt) light. Corneal fluorescein staining will be graded according to the modified Oxford scale (7-point scale: 0, 0.5. 1, 2, 3, 4, 5).

Baseline and at Week 6
Change from baseline at week 6 in bulbar conjunctival hyperemia assessed by Validated Bulbar Redness (VBR) 10 scale (0 to 100), in the study eye.
Tidsramme: Baseline and at Week 6

Bulbar conjunctival redness will be assessed at the slit-lamp examination using white light prior to vital dye instillation and graded according to the VBR 10 scale.

Baseline and at Week 6
Change from baseline over time in ocular itching score assessed by VAS.
Tidsramme: Baseline and at Week 4, Week 6, Week 8, Week 12, and Week 16

The ocular itching VAS ranges from 0 to 100 mm (0 mm = no ocular itching at all, 100 mm = intolerable itching). Participants will be asked to subjectively rate the current severity of ocular itching at each time point.

Baseline and at Week 4, Week 6, Week 8, Week 12, and Week 16
Change from baseline over time in ocular symptoms of itching, tearing, discomfort, mucous discharge, and photophobia on a 4-point scale (0 to 3).
Tidsramme: Baseline and at Week 4, Week 6, Week 8, Week 12, and Week 16

Ocular symptoms are assessed using a 4-point severity scale ranging from 0 (none) to 3 (severe). Five ocular symptoms, itching, tearing, ocular discomfort (including burning, stinging, and foreign body sensation), mucous discharge, and photophobia are evaluated in the study eye. A composite symptom score is described in calculated at screening and Baseline by summing the individual symptom scores, resulting in a total score range of 0 to 15, with higher scores indicating greater symptom severity.

Baseline and at Week 4, Week 6, Week 8, Week 12, and Week 16
Change from baseline over time in corneal fluorescein staining (modified Oxford scale) in the study eye.
Tidsramme: Baseline and at Week 4, Week 6, Week 8, Week 12, and Week 16

Corneal fluorescein staining modified Oxford scale (0-5) as per corneal dot count in each eye.

Baseline and at Week 4, Week 6, Week 8, Week 12, and Week 16
Change from baseline over time in bulbar conjunctival hyperemia assessed by VBR 10 scale (0 to 100) in the study eye.
Tidsramme: Baseline and at Week 4, Week 6, Week 8, Week 12, and Week 16

Bulbar conjunctival hyperemia assessed by Validated Bulbar Redness (VBR) 10 scale (0 to 100).

Baseline and at Week 4, Week 6, Week 8, Week 12, and Week 16
Change from baseline over time in signs of tarsal papillary reaction, corneal neovascularization, cicatrizing conjunctivitis and blepharitis on a 4-point scale (0 to 3) in the study eye.
Tidsramme: Baseline and at Week 4, Week 6, Week 8, Week 12, and Week 16

Change in signs on a 4-point scale (0 to 3) in the study eye.

Baseline and at Week 4, Week 6, Week 8, Week 12, and Week 16
Change from baseline at week 6 and 12 in the QoL scores assessed by the Standardized Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ-S) (assessed in the adult cohort only)
Tidsramme: Baseline and at Week 6 and Week 12.

Standardized Rhinoconjunctivitis QoL Questionnaire (RQLQ[S]) is a validated questionnaire that assesses QoL specifically in patients with rhinoconjunctivitis. There are 28 questions, which are categorized under 7 domains (activities, sleep, non-nose/eye symptoms, practical problems, nasal symptoms, eye symptoms, and emotional). Each question is scored on a 7-point scale from no impairment (score 0) to severe impairment (score 6).

Baseline and at Week 6 and Week 12.
Patient Global Impression of Change (PGIC) at week 6 and week 12 (assessed in the adult cohort only)
Tidsramme: At week 6 and week 12.

PGIC is a short questionnaire used to assess how a participant perceives changes in their condition following treatment, on a scale ranging from 1 to 7.

At week 6 and week 12.
Number of Participants receiving rescue medication over time after week 6
Tidsramme: Week 6 to Week 12

Participants who received rescued medication over time after week 6 (visit 4).

Week 6 to Week 12
Number of participants with treatment-emergent adverse events and serious adverse events (SAEs)
Tidsramme: Up to Week 16

Any adverse events occurring or worsening after the first administration of investigational product is classified as "treatment-emergent" adverse events and does not necessarily have a causal relationship with the intervention. A SAE is any untoward medical occurrence that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of any infectious agent via a medicinal product, and is medically important.

Up to Week 16
Change from baseline over time in best corrected distance visual acuity (BCDVA) in each eye.
Tidsramme: Baseline and at Week 4, Week 6, Week 8, Week 12, and Week 16

Best corrected visual acuity (BCDVA) is determined by careful refraction according to the standard protocol for refraction. BCDVA is measured by Early Treatment of Diabetic Retinopathy Study chart.

Baseline and at Week 4, Week 6, Week 8, Week 12, and Week 16
Change from baseline at week 12 in corneal endothelial cell density in each eye (only at selected sites that have the required equipment).
Tidsramme: Baseline and at week 12

Corneal central region endothelial cell density will be determined for each eye using specular microscopy and expressed as the number of cells/mm2 using the Cell Density readout provided by the software.

Baseline and at week 12
Change from baseline at week 12 in dilated fundus exam in each eye
Tidsramme: Baseline and at week 12

After specular microscopy, mydriatic drops will be instilled in both eyes and once adequate dilation is achieved, a fundal exam shall be performed to examine the vitreous, retina, and optic nerve.

Baseline and at week 12
Change from baseline over time in intraocular pressure in each eye.
Tidsramme: Baseline and at Week 6 and Week 12

IOP will be assessed by tonometry for each eye and will be measured in mmHg.

Baseline and at Week 6 and Week 12
Number of participants discontinued due to tolerability during the treatment period
Tidsramme: Baseline to week 12

Treatment discontinuation rate due to tolerability.

Baseline to week 12

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

1. desember 2025

Primær fullføring (Antatt)

1. mars 2027

Studiet fullført (Antatt)

1. mai 2027

Datoer for studieregistrering

Først innsendt

22. desember 2025

Først innsendt som oppfylte QC-kriteriene

3. februar 2026

Først lagt ut (Faktiske)

9. februar 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

21. september 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

16. september 2026

Sist bekreftet

1. september 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • ICY-AKC-301
  • 2025-522291-83-00 (Ctis)
  • 2025 (U.S. NIH-stipend/kontrakt)

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .